









Markets
/
Stocks
/
nasdaq-cmmb
/

Chemomab Therapeutics Ltd

CMMB



View Detailed Chart

1.890USD

-0.030-1.56%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

46.53MMarket Cap

LossP/E TTM



Chemomab Therapeutics Ltd

1.890

-0.030-1.56%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.56%

5 Days

-14.86%

1 Month

-22.22%

6 Months

-60.63%

Year to Date

-73.90%

1 Year

-71.88%

View Detailed Chart

TradingKey Stock Score of Chemomab Therapeutics Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Chemomab Therapeutics Ltd's Score

Industry at a Glance

Industry Ranking

235 / 501

Overall Ranking

419 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

26.500

Target Price

+867.15%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Chemomab Therapeutics Ltd Highlights

StrengthsRisks

Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Overvalued

The company’s latest PE is -1.57, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.06M shares, increasing 8.03% quarter-over-quarter.